Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dobutamine for hemodynamic insufficiency in very preterm infants
NCT06878742Phase 2Recruiting
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Jun 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dobutamine (5 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Minimum dobutamine dose to reach and maintain a SVC flow above 55 ml/kg/min at 3 hours. Started Jun 2024; status: recruiting.
02
Drugs
dobutamine
Beyond the preview
Go deeper on NCT06878742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878742.